#USA #Seattle #Proteomics #GMJ Technologies #Carol Berry

GMJ Technologies Welcomes Carol Berry as New CEO

GMJ Technologies, a pioneering company in life sciences, has announced the appointment of Carol Berry as the new Chief Executive Officer, effective June 1, 2026. This transition comes as GMJ seeks to enhance its leadership in revolutionizing workflows in protein-based biologics testing and proteomics. Carol takes over from Tosin Dada, PhD, the founder of GMJ Technologies, who will continue as President and Chief Technology Officer, ensuring a seamless transfer of insight and vision.

Who is Carol Berry?

Carol Berry joins GMJ with an impressive pedigree, boasting over 30 years of experience in the life sciences and biotechnology sectors. Most recently, she held the position of Senior Vice President and Chief Business Officer at Caprion Bioscience, now known as CellCarta, where she successfully drove double-digit revenue growth over her nine-year tenure. Her leadership positioned Caprion/CellCarta at the forefront of the specialty contract research laboratory industry, showcasing her ability to navigate complex business landscapes and foster growth.

In her new role at GMJ, Berry will spearhead the company's long-term vision and strategy while ensuring effective communication with stakeholders, the board, and the public. She is set to play a pivotal role in developing funding strategies, establishing partnerships, expanding the market presence of GMJ’s cutting-edge technology, and navigating industry compliance.

Vision for the Future

Expressing her excitement about the new role, Carol Berry stated, "I am thrilled to be joining GMJ Technologies and working with the team to bring its revolutionary technology to the market filling an unmet need for Biologics testing, proteomic research, and several other applications." This statement emphasizes her commitment to pushing the frontiers of biological science through innovative methodologies.

Tosin Dada also expressed his confidence in Berry’s leadership: "I’m truly delighted to welcome Carol to this leadership role at GMJ. She brings a strong track record of leadership and a clear passion for innovation. I’m excited to work alongside her as we bring our novel CE-OptoESI-MS technology to the life sciences industry and expand its impact across a wide range of applications." This partnership is pivotal as GMJ prepares to introduce its groundbreaking technology platform into the market.

The Core Technology

GMJ Technologies is developing a unique solution that aims to revolutionize the analytical workflows associated with proteomics and protein drug testing. The company has innovated a first-of-its-kind capillary electrophoresis platform integrated with an optical-electrospray ionization interface. This technology is designed to enhance the efficiency and accuracy of protein analysis, addressing critical bottlenecks that impair the integration of traditional capillary electrophoresis with mass spectrometry.

The advancements made by GMJ allow faster and more reliable protein analysis across various stages of research, development, and manufacturing. With Berry at the helm, the expectation is that GMJ will accelerate its growth trajectory and further establish itself as a key player in the life sciences field.

As the demands for innovative solutions continue to rise in the realm of biologics, GMJ Technologies, with the leadership of a seasoned expert like Carol Berry, is poised to meet these challenges head-on. The integration of her deep industry knowledge and GMJ’s cutting-edge technology offers a promising future for the company and its stakeholders.

For more information about GMJ Technologies and to read Carol Berry's full biography, please visit GMJ Technologies.